2003 Fiscal Year Final Research Report Summary
Study on the development of anti-diabetic-complications having anti-glycation and antioxidant activities
| Project/Area Number |
13672312
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Meijo University |
|---|
Principal Investigator |
MIWA Ichitomo Meijo University, Fac.of Pharmacy, Professor, 薬学部, 教授 (60076734)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAGUCHI Tadao Meijo University, Fac.of Pharmacy, Assistant Professor, 薬学部, 講師 (50121504)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Keywords | pyridoxal-aminoguanidine adduct / aminoguanidine / diabetic complication / diabetic nephropathy / diabetic neuropathy / diabetic cataract / antioxidant activity |
|---|
| Research Abstract |
1.We compared the inhibitory effect of PL-AG, pyridoxal-aminoguanidine Schiff base, developed by us on nephropathy of diabetic mice with that of aminoguanidine (AG) known as a promising candidate for anti-diabetic-complications. Various parameters such as urinary albumin excretion rate, urine volume, and mesangial volume were improved more markedly by PL-AG than by AG, indicating that PL-AG is superior to AG in preventing diabetic nephropathy.
2.PL-AG was more potent than other compounds such as AG, pyridoxamine, and pyridoxal in in vitro antioxidant activity. In vivo antioxidant activity of PL-AG in diabetic rats was also greater than that of AG. PL-AG was found to act as an antioxidant by reacting with reactive oxygen species to yield a stable oxidized form of PL-AG and by chelating Axansition metal ions.
4.PL-AG did not show any ameliorating effect on the development of diabetes in Goto-Kakizaki rats, a model rat of type 2 diabetes.
|
Research Products
(8 results)
